This study compared the safety and immunogenicity profiles of MF59-adjuvanted , trivalent , influenza vaccine ( ATIV ) and non-adjuvanted , trivalent , influenza vaccine ( TIV ) in Guatemalan children ( N = 360 ) between 6 and < 60 months of age .